SynDevRx is a clinical-stage biotech company developing drug candidates to treat cancers driven by metabolic hormones. Our first application is in combination with the PI3Ka inhibitor alpelisib in breast cancer, where we solve a major issue (hyperglycemia) and have demonstrated synergy with the drug class on efficacy.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):